Related Experiment Video
Updated: Jun 13, 2026
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of
Santiago Montes-Moreno1, Ana-Rosa Gonzalez-Medina, Socorro-María Rodriguez-Pinilla
1Lymphoma Group, Molecular Pathology Programme Spanish National Cancer Research Centre, CNIO, Madrid, Spain. smontes@cnio.es
Background:
Plasmablastic lymphoma has recently come to be considered a distinct entity among mature B cell neoplasms, although the limits with diffuse large B-cell lymphoma (DLBCL) need to be more accurately defined.
Design And Methods:
Here we show the results of an immunohistochemical study of 35 cases of plasmablastic lymphoma compared with a set of 111 conventional DLBCLs.
Results:
Our results demonstrate that the use of a limited combination of immunohistochemical markers (PAX5&CD20, PRDM1/BLIMP1 and XBP1s) enables the identification of a plasmablastic immunophenotype highly characteristic of plasmablastic lymphoma cases and associated with an aggressive clinical behavior. Additionally, the study shows that the acquisition of a partial plasmablastic phenotype (PRDM1/BLIMP1 expression) in DLBCL is associated with shorter survival in R-CHOP-treated patients.
Conclusions:
The use of a restricted combination of immunohistochemical markers (PAX5&CD20, PRDM1/BLIMP1 and XBP1s) enables a more accurate definition of terminal differentiation for large B-cell lymphoma.
